• Consensus Rating: Buy
  • Consensus Price Target: $8.25
  • Forecasted Upside: 367.42%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.77
▼ -0.115 (-6.12%)

This chart shows the closing price for ARAY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Accuray Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARAY

Analyst Price Target is $8.25
▲ +367.42% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Accuray in the last 3 months. The average price target is $8.25, with a high forecast of $9.00 and a low forecast of $7.50. The average price target represents a 367.42% upside from the last price of $1.77.

This chart shows the closing price for ARAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Accuray. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/13/2024Roth CapitalReiterated RatingBuyLow
2/13/2024Roth MkmInitiated CoverageBuy$9.00Low
10/4/2023B. RileyReiterated RatingBuy ➝ Buy$7.50Low
6/24/2022BTIG ResearchLower TargetBuy$9.00 ➝ $7.00Low
6/23/2022B. RileyInitiated CoverageBuy$7.50Low
12/21/2021Loop CapitalInitiated CoverageBuy$7.50Medium
1/7/2021Northland SecuritiesInitiated CoverageOutperformN/A
8/14/2020BTIG ResearchReiterated RatingBuy$6.00High
6/21/2020Lake Street CapitalReiterated RatingBuy$10.00High
6/21/2020CowenReiterated RatingMarket Perform ➝ Average$8.00High
6/17/2020BTIG ResearchReiterated RatingBuy$6.00Medium
1/21/2020BTIG ResearchUpgradeNeutral ➝ Buy$9.50High
8/16/2019Royal Bank of CanadaSet TargetHold$4.00Low
(Data available from 6/24/2019 forward)

News Sentiment Rating

1.12 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/27/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/26/2024
  • 8 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
2/25/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/25/2024
  • 4 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
5/25/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Accuray logo
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Read More

Today's Range

Now: $1.77
Low: $1.76
High: $1.89

50 Day Range

MA: $1.82
Low: $1.49
High: $2.31

52 Week Range

Now: $1.77
Low: $1.46
High: $4.30

Volume

142,009 shs

Average Volume

548,152 shs

Market Capitalization

$175.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Accuray?

The following equities research analysts have issued stock ratings on Accuray in the last year: B. Riley, Roth Capital, Roth Mkm, StockNews.com, and TheStreet.
View the latest analyst ratings for ARAY.

What is the current price target for Accuray?

2 Wall Street analysts have set twelve-month price targets for Accuray in the last year. Their average twelve-month price target is $8.25, suggesting a possible upside of 367.4%. Roth Mkm has the highest price target set, predicting ARAY will reach $9.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $7.50 for Accuray in the next year.
View the latest price targets for ARAY.

What is the current consensus analyst rating for Accuray?

Accuray currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARAY will outperform the market and that investors should add to their positions of Accuray.
View the latest ratings for ARAY.

What other companies compete with Accuray?

How do I contact Accuray's investor relations team?

Accuray's physical mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider's listed phone number is (408) 716-4600 and its investor relations email address is [email protected]. The official website for Accuray is www.accuray.com. Learn More about contacing Accuray investor relations.